Regenxbio Inc [RGNX] stock prices are up 3.85% to $11.34 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RGNX shares have gain 6.08% over the last week, with a monthly amount glided 23.26%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Regenxbio Inc [NASDAQ: RGNX] stock has seen the most recent analyst activity on February 11, 2025, when Goldman downgraded its rating to a Neutral and also revised its price target to $14 from $38. Goldman initiated its recommendation with a Buy and recommended $38 as its price target on June 07, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on March 11, 2024, and assigned it a price target of $36. In a note dated March 08, 2024, RBC Capital Mkts upgraded an Outperform rating on this stock and boosted its target price from $20 to $35.
The stock price of Regenxbio Inc [RGNX] has been fluctuating between $5.03 and $12.84 over the past year. Currently, Wall Street analysts expect the stock to reach $30.14 within the next 12 months. Regenxbio Inc [NASDAQ: RGNX] shares were valued at $11.34 at the most recent close of the market. An investor can expect a potential return of 165.78% based on the average RGNX price forecast.
Analyzing the RGNX fundamentals
The Regenxbio Inc [NASDAQ:RGNX] reported sales of 155.78M for trailing twelve months, representing a drop of -4.20%. Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at -1.06%, Pretax Profit Margin comes in at -1.13%, and Net Profit Margin reading is -1.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.67 and Total Capital is -0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Regenxbio Inc [NASDAQ:RGNX]’s Current Ratio is 3.13. As well, the Quick Ratio is 3.13, while the Cash Ratio is 0.67. Considering the valuation of this stock, the price to sales ratio is 3.68, the price to book ratio is 2.67.
Transactions by insiders
Recent insider trading involved Simpson Curran, Chief Executive Officer, that happened on Oct 09 ’25 when 20811.0 shares were sold. Director, CURRAN M SIMPSON completed a deal on Oct 09 ’25 to buy 20811.0 shares. Meanwhile, Chief Executive Officer Simpson Curran sold 7624.0 shares on Sep 29 ’25.
